QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.74 (-0.64%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.96 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-1.45%)
GE   106.30 (+0.22%)
DIS   91.95 (-0.63%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.74 (-0.64%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.96 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-1.45%)
GE   106.30 (+0.22%)
DIS   91.95 (-0.63%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.74 (-0.64%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.96 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-1.45%)
GE   106.30 (+0.22%)
DIS   91.95 (-0.63%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.74 (-0.64%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.96 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-1.45%)
GE   106.30 (+0.22%)
DIS   91.95 (-0.63%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
NASDAQ:IVVD

Invivyd (IVVD) Stock Forecast, Price & News

$1.30
-0.05 (-3.70%)
(As of 06/9/2023 ET)
Compare
Today's Range
$1.27
$1.35
50-Day Range
$1.08
$1.80
52-Week Range
$1.03
$4.90
Volume
200,309 shs
Average Volume
226,420 shs
Market Capitalization
$142.32 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00

Invivyd MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
130.8% Upside
$3.00 Price Target
Short Interest
Bearish
8.19% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.35) to ($0.98) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.46 out of 5 stars

Medical Sector

915th out of 987 stocks

Biological Products, Except Diagnostic Industry

153rd out of 159 stocks


IVVD stock logo

About Invivyd (NASDAQ:IVVD) Stock

Invivyd, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is adintrevimab, a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. It also has discovery stage candidates for the prevention of seasonal influenza. Invivyd, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is based in Waltham, Massachusetts.

Receive IVVD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Invivyd and its competitors with MarketBeat's FREE daily newsletter.

IVVD Stock News Headlines

Free Stock Analysis Report: Get Buy, Sell, or Hold Recommendation
Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation.
Invivyd: Q1 Earnings Insights
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
4IVVD : Earnings Preview: Invivyd
HC Wainwright Initiates Coverage on Invivyd (NASDAQ:IVVD)
See More Headlines

IVVD Price History

IVVD Company Calendar

Last Earnings
3/23/2023
Today
6/09/2023
Next Earnings (Estimated)
8/21/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IVVD
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.00
High Stock Price Forecast
$5.00
Low Stock Price Forecast
$1.00
Forecasted Upside/Downside
+129.0%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

Net Income
$-241,320,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.27 per share

Miscellaneous

Free Float
88,571,000
Market Cap
$143.42 million
Optionable
Optionable
Beta
0.11

Key Executives

  • Mr. David Hering M.B.A. (Age 47)
    CEO & Director
    Comp: $453.76k
  • Ms. Jill Andersen J.D. (Age 49)
    Chief Legal Officer & Corp. Sec.
    Comp: $580.12k
  • Ms. Laura Walker Ph.D. (Age 37)
    Co-Founder & Chief Scientific Officer
  • Mr. Frederick W. Driscoll (Age 71)
    Interim CFO, Principal Financial Officer & Principal Accounting Officer
  • Mr. Jeremy Gowler
    Chief Operating & Commercial Officer
  • Dr. Rebecca Dabora Ph.D. (Age 63)
    Chief Technology & Manufacturing Officer
  • Kyra Rosow Faircloth
    VP of Gov. Affairs, Advocacy & Corp. Communication
  • Dr. Peter C. Schmidt M.D.
    M.Sc., Chief Medical Officer













IVVD Stock - Frequently Asked Questions

Should I buy or sell Invivyd stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Invivyd in the last twelve months. There are currently 1 sell rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" IVVD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IVVD, but not buy additional shares or sell existing shares.
View IVVD analyst ratings
or view top-rated stocks.

What is Invivyd's stock price forecast for 2023?

2 analysts have issued 12-month target prices for Invivyd's shares. Their IVVD share price forecasts range from $1.00 to $5.00. On average, they predict the company's stock price to reach $3.00 in the next year. This suggests a possible upside of 129.0% from the stock's current price.
View analysts price targets for IVVD
or view top-rated stocks among Wall Street analysts.

How have IVVD shares performed in 2023?

Invivyd's stock was trading at $1.50 at the start of the year. Since then, IVVD shares have decreased by 12.7% and is now trading at $1.31.
View the best growth stocks for 2023 here
.

When is Invivyd's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023.
View our IVVD earnings forecast
.

How were Invivyd's earnings last quarter?

Invivyd, Inc. (NASDAQ:IVVD) posted its quarterly earnings results on Thursday, March, 23rd. The company reported ($0.41) EPS for the quarter, missing analysts' consensus estimates of ($0.39) by $0.02.

What ETF holds Invivyd's stock ?

ETFMG Treatments Testing and Advancements ETF holds 35,155 shares of IVVD stock, representing 0.23% of its portfolio.

What is Invivyd's stock symbol?

Invivyd trades on the NASDAQ under the ticker symbol "IVVD."

Who are Invivyd's major shareholders?

Invivyd's stock is owned by a number of institutional and retail investors. Top institutional investors include FMR LLC (12.76%), Alphabet Inc. (5.20%), BlackRock Inc. (3.45%), Slate Path Capital LP (3.42%), Bain Capital Life Sciences Investors LLC (1.77%) and Maverick Capital Ltd. (1.73%).

How do I buy shares of Invivyd?

Shares of IVVD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Invivyd's stock price today?

One share of IVVD stock can currently be purchased for approximately $1.31.

How much money does Invivyd make?

Invivyd (NASDAQ:IVVD) has a market capitalization of $143.42 million. The company earns $-241,320,000.00 in net income (profit) each year or ($1.62) on an earnings per share basis.

How can I contact Invivyd?

Invivyd's mailing address is 1601 TRAPELO ROAD SUITE 178, WALTHAM MA, 02451. The official website for the company is adagiotx.com. The company can be reached via phone at 781-819-0080 or via email at investors@adagiotx.com.

This page (NASDAQ:IVVD) was last updated on 6/9/2023 by MarketBeat.com Staff

My Account -